BioSpace News Archive

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its full-year 2022 financial results on Thursday, March 30, 2023.

Vifor Fresenius Medical Care Renal Pharma is pleased to announce that Tavneos® has been included in the revised EULAR AAV management recommendations, as one of several important updates in the 2022 version.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems.

Evotec SE reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.

EnteroBiotix Limited announced the initiation of a multi-centre randomised double-blind placebo controlled Phase 2 clinical trial.

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced Phase 1a results for ZP8396, the company’s amylin analogue.

Backed by international investors, Atrandi Biosciences is establishing a direct team to support customers in the U.S. and advancing the global commercialization of its breakthrough microfluidic and single-cell analysis technologies.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced positive results from the company’s Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735.

WuXi Biologics (“WuXi Bio”) (2269.HK) congratulates its strategic partner Amicus Therapeutics (“Amicus”) (Nasdaq: FOLD) on receiving European Commission’s approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).